Fintel reports that on January 28, 2026, Barclays upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Equal-Weight to Overweight.
Analyst Price Forecast Suggests 10.98% Upside
As of January 13, 2026, the average one-year price target for PTC Therapeutics is $83.91/share. The forecasts range from a low of $55.55 to a high of $123.90. The average price target represents an increase of 10.98% from its latest reported closing price of $75.61 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for PTC Therapeutics is 1,143MM, a decrease of 35.76%. The projected annual non-GAAP EPS is -4.99.
What is the Fund Sentiment?
There are 622 funds or institutions reporting positions in PTC Therapeutics. This is an decrease of 10 owner(s) or 1.58% in the last quarter. Average portfolio weight of all funds dedicated to PTCT is 0.23%, an increase of 29.37%. Total shares owned by institutions increased in the last three months by 4.59% to 94,322K shares. 
The put/call ratio of PTCT is 0.81, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 7,746K shares representing 9.65% ownership of the company. No change in the last quarter.
Wellington Management Group Llp holds 4,919K shares representing 6.13% ownership of the company. In its prior filing, the firm reported owning 4,694K shares , representing an increase of 4.56%. The firm decreased its portfolio allocation in PTCT by 82.03% over the last quarter.
Janus Henderson Group holds 3,774K shares representing 4.70% ownership of the company. In its prior filing, the firm reported owning 3,175K shares , representing an increase of 15.86%. The firm decreased its portfolio allocation in PTCT by 46.36% over the last quarter.
Armistice Capital holds 3,277K shares representing 4.08% ownership of the company. In its prior filing, the firm reported owning 4,735K shares , representing a decrease of 44.49%. The firm decreased its portfolio allocation in PTCT by 25.24% over the last quarter.
Toronto Dominion Bank holds 3,247K shares representing 4.04% ownership of the company. In its prior filing, the firm reported owning 2,446K shares , representing an increase of 24.66%. The firm decreased its portfolio allocation in PTCT by 42.21% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
